VYNE Therapeutics (NASDAQ:VYNE) Shares Scheduled to Reverse Split on Monday, July 27th

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) are set to reverse split on the morning of Monday, July 27th. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, July 26th.

VYNE Therapeutics Stock Performance

Shares of NASDAQ:VYNE opened at $0.90 on Thursday. VYNE Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $1.59. The business has a 50-day simple moving average of $0.68 and a two-hundred day simple moving average of $0.63. The firm has a market cap of $29.96 million, a price-to-earnings ratio of -2.36 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last posted its earnings results on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.10. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. As a group, research analysts predict that VYNE Therapeutics will post -1.1 earnings per share for the current year.

VYNE Therapeutics Dividend Announcement

The business also recently disclosed a special dividend, which will be paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd will be given a dividend of $0.38 per share.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Hedge Funds Weigh In On VYNE Therapeutics

Several institutional investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in shares of VYNE Therapeutics during the 2nd quarter worth $206,000. Adage Capital Partners GP L.L.C. increased its position in VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after buying an additional 300,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of VYNE Therapeutics in the second quarter worth about $176,000. Two Sigma Investments LP bought a new position in shares of VYNE Therapeutics in the third quarter worth about $74,000. Finally, Shay Capital LLC purchased a new position in shares of VYNE Therapeutics during the 3rd quarter valued at about $165,000. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.